LXEO Logo

Lexeo Therapeutics, Inc. Common Stock (LXEO) 

NASDAQ$3.07
Market Cap
$101.51M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
288 of 924
Rank in Industry
165 of 527

LXEO Insider Trading Activity

LXEO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$104,852111
Sells
$179,147889

Related Transactions

CHOLMONDELEY PAULA Hdirector1$104,8520$0$104,852
See Tai SandiChief Development Officer0$01$6,558$-6,558
Robertson JennyChief Legal Officer0$01$9,272$-9,272
Adler EricChief Medical Officer0$01$10,410$-10,410
Townsend Richard NolanChief Executive Officer0$05$152,908$-152,908

About Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. …

Insider Activity of Lexeo Therapeutics, Inc. Common Stock

Over the last 12 months, insiders at Lexeo Therapeutics, Inc. Common Stock have bought $104,852 and sold $179,147 worth of Lexeo Therapeutics, Inc. Common Stock stock.

On average, over the past 5 years, insiders at Lexeo Therapeutics, Inc. Common Stock have bought $5.05M and sold $179,147 worth of stock each year.

Highest buying activity among insiders over the last 12 months: CHOLMONDELEY PAULA H (director) — $104,852.

The last purchase of 15,000 shares for transaction amount of $104,852 was made by CHOLMONDELEY PAULA H (director) on 2024‑11‑25.

List of Insider Buy and Sell Transactions, Lexeo Therapeutics, Inc. Common Stock

2025-02-19SaleTownsend Richard NolanChief Executive Officer
4,326
0.0133%
$4.41$19,091-33.71%
2025-02-19SaleAdler EricChief Medical Officer
2,359
0.0073%
$4.41$10,410-33.71%
2025-02-19SaleRobertson JennyChief Legal Officer
2,101
0.0065%
$4.41$9,272-33.71%
2025-02-19SaleSee Tai SandiChief Development Officer
1,486
0.0046%
$4.41$6,558-33.71%
2024-12-10SaleTownsend Richard NolanChief Executive Officer
2,500
0.0076%
$8.20$20,491-35.17%
2024-11-25PurchaseCHOLMONDELEY PAULA Hdirector
15,000
0.0385%
$6.99$104,852-22.41%
2024-11-11SaleTownsend Richard NolanChief Executive Officer
2,500
0.0072%
$7.82$19,557-26.16%
2024-10-10SaleTownsend Richard NolanChief Executive Officer
5,000
0.0149%
$8.10$40,496-19.72%
2024-09-10SaleTownsend Richard NolanChief Executive Officer
5,000
0.0196%
$10.65$53,274-32.75%
2023-11-07PurchaseLongitude Capital Partners IV, LLC10 percent owner
454,545
1.8373%
$11.00$5M+25.53%
2023-11-07PurchaseOmega Fund VI, L.P.10 percent owner
454,545
1.8373%
$11.00$5M+25.53%
Total: 11
*Gray background shows transactions not older than one year

Insider Historical Profitability

25.53%
CHOLMONDELEY PAULA Hdirector
30627
0.0926%
$94,024.8910
Longitude Capital Partners IV, LLC10 percent owner
2567100
7.7636%
$7.88M10+25.53%
Omega Fund VI, L.P.10 percent owner
2157623
6.5252%
$6.62M10+25.53%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$12,784,645
193
20.49%
$111.89M
$22,597,521
91
4.59%
$104.68M
$47,282,828
47
-17.38%
$96.94M
$7,147,964
34
24.78%
$96.35M
$36,079,815
31
43.23%
$103.59M

LXEO Institutional Investors: Active Positions

Increased Positions59+103.51%4M+12.79%
Decreased Positions19-33.33%4M-13.53%
New Positions29New1MNew
Sold Out Positions9Sold Out976,915Sold Out
Total Postitions97+70.18%29M-0.74%

LXEO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Janus Henderson Group Plc$12,410.0013.15%4.34M+576,059+15.31%2024-12-31
Citadel Advisors Llc$7,789.008.25%2.72M00%2024-12-31
Adage Capital Partners Gp, L.L.C.$6,319.006.7%2.21M-388,121-14.94%2024-12-31
D1 Capital Partners L.P.$6,303.006.68%2.2M-302,707-12.08%2024-12-31
Blackrock, Inc.$5,211.005.52%1.82M+191,679+11.76%2024-12-31
Eventide Asset Management, Llc$3,532.003.74%1.23M-621,152-33.47%2024-12-31
Vestal Point Capital, Lp$3,432.003.64%1.2M+350,000+41.18%2024-12-31
Omega Fund Management, Llc$3,388.003.59%1.18M-1M-49.72%2024-12-31
Blackstone Inc.$3,314.003.51%1.16M00%2024-12-31
Novo Holdings A/S$3,211.003.4%1.12M00%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.